Assay Kit suits high-throughput environments.
Press Release Summary:
CellProbe HT Caspase 3/7 Whole Cell Assay Kit enables apoptosis detection and can be automated on Biomek® liquid handling workstations. Microtiter plate assay kit is available with protocols for 96- and 384-well assay formats. Plate-based assay kit requires no protease inhibitors or mixing. Eliminating cell lysis and washing steps, it streamlines liquid handling.
Original Press Release:
Caspase 3/7 Whole Cell Assay Kits are First in New CellProbe(TM) HT Product Line
Fullerton, California, October, 2002 - Beckman Coulter, Inc. introduces a new line of high-throughput fluorogenic kits for cell-based assays. The first of these kits, the CellProbe HT Caspase 3/7 Whole Cell Assay Kit, enables apoptosis detection, an important assay in the development of therapeutics. CellProbe HT assays are whole cell based and can be automated on Biomek® liquid handling workstations. The automation of caspase assays makes it feasible to use them in high-throughput drug discovery applications, such as primary and secondary screening, delivering important information to researchers earlier in the drug discovery process. The microtiter plate assay kits are available with protocols for 96- and 384-well assay formats. Based on whole cell detection technology, the new CellProbe plate-based assay kits require no protease inhibitors or mixing. By eliminating cell lysis and washing steps, the kits streamline liquid handling for easy automation. CellProbe HT's high specificity enables researchers to easily measure activity in whole cells for detection of small changes in enzyme activity. "CellProbe HT chemistries expand our offering of complete cell-based screening solutions." commented Peter Louie, Strategic Product Marketing Manager for Beckman Coulter. "Combining these chemistries with our advanced automation and liquid handling technologies enables us to offer assay kits that are optimized for the high-throughput environment." Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services. For more information, access the Beckman Coulter World Wide Web Information Service at www.beckmancoulter.com or call (800) 742-2345 (U.S.). Fax (800) 643-4366 (U.S.). From outside the U.S. call (714) 871-4848, or Fax (714) 773-6611.
